|
|
 |
|
Viewing report
|
|
|
|
Shire plc: PharmaVitae Profile
Datamonitor, Dec 2010, Pages: 62
Introduction
This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Shire's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Strategic insight into the prospects for Shire over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
- Shire has pulled off the feat of overcoming the loss of its largest product by a long way, Adderall XR. Assess the strategies used to achieve this.
- Diversifying away from key historical markets such as ADHD, Shire has built an enviable portfolio of treatments for rare genetic disorders.
|
|
|
|
